Detail akcie Century Therap Rg online

Business Summary: Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Century Therapeutics Inc revenues increased from $2.4M to $109.2M. Net income totaled $9.6M vs. loss of $90.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Biotechnology segment income totaling $3.4M vs. loss of $100.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.20 to $0.11.